Please assess the completion status of the following clinical trial:

Trial Title: Prospective Prolaris Value and Efficacy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (\<= 6 months), untreated patients with histologically proven adenocarcinoma of the prostate~* Final treatment decision has not been made (that is all treatment options are feasible and none have been ruled out due to comorbidities at study entry)~* Clinically localized (no evidence on clinical or imaging studies of advanced disease)~* No hormonal therapy for treatment of prostate cancer including LHRH agonist or antagonist, anti-androgen, estrogens or exogenous androgens when applicable (use of 5-alpha reductase inhibitors is acceptable)~* Sufficient amount of tissue remains from biopsy to perform genomic testing~* Life expectance of a minimum of 10 years~* Men who completed PART 1 and were treated with radical prostatectomy (including robotic, laparoscopic, open retropubic or perineal) or receive radiation therapy or were placed on AS or WW.~Exclusion Criteria:~* Men with clinical node positive or metastatic disease~* Men with a known baseline total serum testosterone level of \<100 ng/dL prior to radiation or hormone therapy (men with unknown baseline testosterone levels will not be excluded)~* Men who previously received pelvic radiotherapy for another malignancy~* Non adenocarcinoma prostate cancer histologies

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Stage Prostate Cancer (Type: None): Recently diagnosed treatment-naïve patients with early stage localized prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).